Company intelligence / Profile preview
Beijing Kejing Biotechnology
Beijing, Beijing Shi, China
- Ownership
- Private
- Development stage
- Other
01
Overview
All known pipeline assets are currently at the pre-clinical stage with no published clinical results as of June 2025. The company's lead asset targets mesothelin via a CAR-NK approach for solid tumors; another program targets acute myeloid leukemia using an undisclosed modality/platform. There is also an early-stage cardiovascular disease program under development.
- Therapeutic areas
- OncologyEndocrinologyCardiovascularHematology
- Modalities
- CAR-NK cell therapyNatural Killer Cell TherapiesCAR-T cell therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Beijing Kejing Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Kejing Biotechnology.